New hope for tough pancreatic tumors: drug combo aims to shrink cancer before surgery
NCT ID NCT07436741
Summary
This study is testing if adding a drug called surufatinib to standard chemotherapy helps people with high-risk pancreatic cancer that can be removed by surgery. The goal is to see if the three-drug combination shrinks tumors better before surgery, leading to more successful operations and longer survival. About 106 adults with specific types of pancreatic cancer will be randomly assigned to receive either the standard two-drug chemo or the new three-drug combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.